Low Temperature Sterilization Market: as the EPA April 5 2024 Final Air Toxics Rule for EtO Sterilization Facilities at 89 FR 24090 mandating 90% ethylene oxide emission reduction with compliance retrofits estimated at USD 2.00 Million to USD 8.00 Million per facility compels commercial sterilizer operators to transition from legacy EtO chambers to hydrogen peroxide vapor systems generating no carcinogenic off-gas, the FDA January 2024 recognition of vaporized hydrogen peroxide as an Established Category A sterilization method shortening 510(k) review times by approximately 90 days provides the regulatory pathway incentive for VHP adoption, so ASP STERRAD hydrogen peroxide gas plasma with over 22,000 installations globally and STERIS Healthcare Q4 FY2024 revenue of USD 1,007.90 Million at 14% growth confirm the commercial momentum sustaining the transition.

The global low temperature sterilization market size was USD 4.24 Billion in 2025 and is expected to register a revenue CAGR of 8.4% during the forecast period. Market revenue growth is driven by factors such as the EPA April 2024 Final Air Toxics Rule mandating 90% ethylene oxide emission reduction at commercial sterilizer facilities with USD 2.00 Million to USD 8.00 Million compliance retrofit costs compelling EtO operators to transition to hydrogen peroxide vapor sterilization, the FDA January 2024 recognition of vaporized hydrogen peroxide as an Established Category A sterilization method shortening 510(k) review times for VHP-compatible devices, and as well as the proliferation of heat-sensitive robotic surgical instruments and polymer-based medical devices that cannot be processed in 121-degree Celsius steam autoclaves and require low temperature hydrogen peroxide or EtO sterilization as the only validated alternative. The first driving factor is the EPA April 5 2024 Final Air Toxics Rule published in the Federal Register at 89 FR 24090, mandating that all affected commercial sterilizer facilities reduce EtO emissions by installing new control technologies within two to three years, with compliance retrofits estimated at USD 2.00 Million to USD 8.00 Million per facility per published regulatory analyses, compelling EtO operators to evaluate whether to retrofit existing EtO chambers or replace EtO capacity with hydrogen peroxide vapor sterilization systems that inherently produce no EtO carcinogenic off-gas. STERIS plc reported that Healthcare segment Q4 fiscal 2024 revenue grew 14% to USD 1,007.90 Million compared with USD 884.60 Million in Q4 fiscal 2023 per the company fiscal year 2024 full year financial results, reflecting 19% improvement in capital equipment revenue, 14% growth in consumable revenue, and 9% growth in service revenue across the sterilization equipment and consumables portfolio. Advanced Sterilization Products, a wholly-owned Fortive Corporation subsidiary since Fortive completed the acquisition from Johnson & Johnson's Ethicon division for approximately USD 2.70 Billion in April 2019, has a global installed base of over 22,000 STERRAD systems per ASP product communications, with the STERRAD system being the first hydrogen peroxide terminal sterilization system ASP developed and introduced. On 1 January 2024, the US Food and Drug Administration recognized vaporized hydrogen peroxide as an Established Category A sterilization method, per published analyses of the FDA sterilization guidance, shortening 510(k) review times by approximately 90 days for medical devices labelled as compatible with VHP sterilization and incentivising device designers to prioritize hydrogen peroxide compatibility for new product designs. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way NHS UK guidance issued in March 2025 requiring flexible endoscopes to undergo low temperature sterilization or high-level disinfection within 4 hours of use creates immediate compliance capital equipment demand at NHS hospital endoscopy departments, which allows the regulatory compliance requirement to convert what would otherwise be a discretionary capital budget item into a non-discretionary patient safety compliance procurement at NHS trusts across England. Once an NHS endoscopy unit must comply with the 4-hour LTS processing requirement, the hospital either requires additional low temperature sterilization capacity to process scopes within the compliance window or it faces regulatory non-compliance at NHS inspection, so the endoscope LTS capital equipment procurement becomes a compliance-driven non-discretionary commitment tied to a specified regulatory deadline rather than a discretionary long-term capital plan. As a result, demand and revenue share are concentrating around the LTS platforms with the specific clinical indications for flexible endoscope sterilization including duodenoscopes and bronchoscopes, and the forecast tilts toward these endoscope-indicated LTS platforms rather than general-purpose sterilization capital equipment without specific endoscope compatibility claims. For instance, in March 2026, the Trump administration EPA proposed reconsideration of the 2024 Final EtO Rule per the Federal Register notice at 91 FR 12700, introducing regulatory uncertainty about the compliance timeline but not altering the long-term regulatory trajectory toward lower EtO exposure given EtO's known carcinogenicity. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the complementary EPA regulatory pressure on EtO and FDA regulatory incentive for VHP that jointly create an accelerated commercial transition from ethylene oxide to hydrogen peroxide-based low temperature sterilization at hospital central sterile supply departments and commercial contract sterilization facilities. The EPA and FDA dual regulatory mechanism works commercially because the EPA April 5 2024 Final Air Toxics Rule at 89 FR 24090 quantifies the compliance cost burden for EtO operators at USD 2.00 Million to USD 8.00 Million per facility for emission control retrofit, a capital outlay that many hospital CSSD departments and smaller commercial EtO sterilization facilities find comparable in magnitude to the capital cost of replacing EtO capacity with VHP systems that inherently require no carcinogenic off-gas emission controls. The EPA's own documentation of the 2024 final rule stated that the safeguards would eliminate over 90% of ethylene oxide emissions from commercial sterilizer facilities and reduce the number of people exposed to unacceptable cancer risks from ethylene oxide by 92%, per the Earthjustice summary of the EPA rule. The FDA recognition of VHP as an Established Category A sterilization method in January 2024 simultaneously reduces the 510(k) review time for medical devices validated as VHP-compatible by approximately 90 days, creating a commercial incentive for medical device manufacturers designing heat-sensitive products to engineer VHP sterilization compatibility into new device designs from the outset. ASP, wholly owned by Fortive Corporation since Fortive completed the acquisition from Johnson & Johnson's Ethicon subsidiary for approximately USD 2.70 Billion in April 2019, has built an installed base of over 22,000 STERRAD systems globally per ASP product communications. The STERRAD 100NX with ALLClear Technology provides up to five sterilization cycle types including a ULTRA GI cycle that is the first hydrogen peroxide gas plasma sterilization method indicated for duodenoscope reprocessing in the US market, per ASP product documentation. These are some of the key factors driving revenue growth of the market.

The second driver is the confirmed sustained commercial demand for low temperature sterilization capital equipment and consumables demonstrated by STERIS fiscal 2024 segment financial performance and the new NHS compliance requirement that creates non-discretionary endoscope LTS capital procurement demand at NHS hospital endoscopy departments. Commercial demand confirmation works because STERIS Healthcare segment Q4 FY2024 revenue reaching USD 1,007.90 Million at 14% growth with capital equipment revenue growing 19% and consumable revenue growing 14% per the STERIS fiscal year 2024 Q4 and full year earnings release demonstrates that hospital CSSD capital investment in sterilization equipment rebounded strongly as deferred surgical procedure volumes recovered in 2024, driving instrument sterilization cycle volume and consumable cassette demand at the hospital level. STERIS Applied Sterilization Technologies segment Q4 FY2024 revenue grew 5% to USD 250.90 Million, confirming commercial contract sterilization services growth at the medical device manufacturer end-user segment alongside hospital CSSD demand. The NHS UK guidance issued in March 2025 requiring flexible endoscopes to undergo low temperature sterilization or high-level disinfection within 4 hours of use, per published regulatory analyses, creates immediate compliance capital equipment demand at NHS hospital endoscopy departments that currently process scopes at the end of a procedure list rather than within 4 hours, converting what would otherwise be a multi-year capital plan into a compliance-driven procurement with a specified regulatory timeline. ASP's STERRAD 100NX with the ULTRA GI cycle specifically indicated for duodenoscope sterilization is the primary LTS solution positioned to address NHS endoscopy compliance procurement alongside STERIS V-PRO VHP systems. European ISO 10993-7 residual limit guidance harmonization with US standards in October 2024 per published regulatory analyses simplifies trans-Atlantic sterilization validation for multinational medical device manufacturers. These are some of the key factors driving revenue growth of the market.

STERIS Healthcare segment Q4 FY2024 revenue reached USD 1,007.90 Million at 14% year-on-year growth, with capital equipment revenue growing 19% and consumable revenue growing 14%. ASP STERRAD systems surpass 22,000 global installations generating recurring cassette and cartridge consumable revenue per cycle above the capital equipment procurement base. Together these two primary-source commercial anchors confirm that the low temperature sterilization capital and consumable market entered 2025 with above-market-growth commercial momentum sustained by surgical volume rebound, EtO-to-VHP technology transition, and endoscope compliance procurement.

The third driver is the structural expansion of the heat-sensitive instrument category requiring low temperature sterilization as robotic surgery adoption creates a large and growing population of articulated wrist mechanisms, camera endoscopes, light cables, polymer-coated instrument shafts, and electronic sensor-equipped surgical tools that degrade under steam autoclave processing conditions. Heat-sensitive instrument demand works commercially because each hospital that adopts a robotic surgery programme generates ongoing demand for low temperature sterilization capacity to process the da Vinci robotic instrument set between cases, and the growing competitive robotic surgery platform ecosystem including Medtronic Hugo, CMR Surgical Versius, and Johnson & Johnson Ottava alongside Intuitive Surgical da Vinci creates additional heat-sensitive instrument populations at each new robotic programme adoption. Published analyses note that elective surgical procedure volume rebounded 12% in 2024 as deferred procedures were completed, straining legacy steam sterilization capacity in hospital CSSD departments and driving evaluation of low temperature alternatives for instrument categories that had previously been processed by steam sterilization despite marginal compatibility. Japan's Ministry of Health, Labour and Welfare enforces stringent sterilization standards for medical device reprocessing requiring hydrogen peroxide gas plasma sterilization for heat-sensitive surgical instruments at major academic medical centres. China's rapidly expanding surgical infrastructure at tier-1 and tier-2 hospitals including robotic surgery programme development is expanding the heat-sensitive instrument pool requiring low temperature sterilization, driving ASP, STERIS, and Getinge equipment procurement. These are some of the key factors driving revenue growth of the market.

However, the low temperature sterilization market faces adoption constraints from the high upfront capital cost of VHP and H2O2 plasma systems creating barriers for smaller hospitals and ASCs, the higher per-cycle operating cost of H2O2 plasma cassettes at approximately USD 15.00 to USD 40.00 per cycle versus USD 1.00 to USD 5.00 for EtO sterilization at high-volume commercial facilities, and the regulatory uncertainty introduced by the Trump administration EPA March 2026 proposed reconsideration of the 2024 EtO Final Rule at 91 FR 12700. The Iran-US sanctions and the escalation of the United States-Iran confrontation in late February 2026 disrupted specialty fluorinated polymer and petrochemical precursor supply chains routed through Strait of Hormuz corridors that feed into H2O2-resistant sterilization chamber seal and lining manufacturing, adding materials procurement cost pressure for STERRAD and VHP system manufacturers through Q1 and Q2 2026. Ethylene oxide remains clinically necessary for a subset of medical devices including certain polymer implants, long-channel catheters, and devices incompatible with both hydrogen peroxide and steam sterilization, as the EPA stated in its March 2026 proposed reconsideration that EtO is the only safe and effective sterilization method for many medical devices including heart valves, pacemakers, surgical kits, and ventilators, limiting complete EtO substitution by hydrogen peroxide alternatives for all low temperature applications. These factors substantially limit low temperature sterilization market growth over the forecast period.

Based on technology, the global low temperature sterilization market is segmented into ethylene oxide sterilizers, hydrogen peroxide gas plasma sterilizers, vaporized hydrogen peroxide sterilizers, and other methods including ozone and low temperature steam formaldehyde. Ethylene oxide sterilizers account for approximately 46% of 2025 market revenue as the historically dominant technology, primarily in contract sterilization applications for large-volume medical device manufacturing where EtO compatibility and validated regulatory submissions make technology transition strategically complex. Hydrogen peroxide gas plasma sterilizers, led by ASP STERRAD with over 22,000 global installations, account for approximately 28% of 2025 market revenue and are growing at the fastest rate within the market driven by the EPA April 2024 EtO emission rule, FDA VHP Established Category A January 2024 designation, NHS March 2025 endoscope LTS requirement, and the growing instrument categories of heat-sensitive robotic and electronic surgical tools. Vaporized hydrogen peroxide systems, led by STERIS V-PRO, account for approximately 16% of 2025 market revenue and benefit from rapid cycle times, zero carcinogenic byproducts, and compatibility with flexible endoscopes and polymer-based medical device materials.

Based on device type, endoscopes accounted for the largest segment revenue share in the low temperature sterilization market in 2024. The flexible endoscope category, encompassing gastroscopes, colonoscopes, duodenoscopes, bronchoscopes, and ureteroscopes, requires sterilization or high-level disinfection between each patient use due to heat-sensitive optics, channels, and polymer body construction that precludes autoclave processing. Duodenoscopes with complex elevator mechanisms that proved difficult to adequately disinfect using standard high-level disinfection generated HAI outbreaks from carbapenem-resistant Enterobacteriaceae at multiple US hospitals, leading the FDA to require duodenoscope manufacturers to transition to models with disposable tip mechanisms or devices compatible with terminal sterilization. ASP STERRAD 100NX received US market clearance for the ULTRA GI cycle specifically indicated for duodenoscope sterilization per ASP product documentation, making it the primary LTS capital equipment solution positioned to address both US FDA duodenoscope compliance and NHS March 2025 flexible endoscope 4-hour LTS requirements.

Based on regional analysis, the low temperature sterilization market in North America accounted for the largest revenue share in 2025 at approximately 38% of global revenue. The United States drives the regional position through OSHA worker protection standards, CMS hospital-acquired condition penalties incentivising sterilization infrastructure investment, and the commercial concentration of ASP (STERRAD) and STERIS (V-PRO, AST) in the US healthcare sterilization market. The EPA April 2024 Final EtO Rule at 89 FR 24090 is a US-specific regulatory driver creating commercial urgency not yet replicated in European or Asian markets, establishing a US-specific EtO-to-VHP technology transition dynamic. Fluorinated polymer component manufacturing for sterilization chamber seals is primarily concentrated in North American and European production facilities, and the Iran-US sanctions escalation in late February 2026 does not materially disrupt ASP or STERIS primary manufacturing given domestic US production capability for critical H2O2-resistant components.

The market in Europe is expected to register a rapid revenue growth rate over the forecast period. Germany, France, the United Kingdom, Italy, and Spain represent the five largest national low temperature sterilization markets. The NHS UK guidance issued in March 2025 requiring flexible endoscopes to undergo low temperature sterilization or high-level disinfection within 4 hours of use creates immediate compliance capital equipment demand across NHS hospital endoscopy departments. ISO 10993-7 residual limit guidance harmonization between EU and US regulators in October 2024 simplifies VHP and EtO sterilization validation for multinational medical device manufacturers, reducing the dual-validation burden that previously required separate testing to different residual limits. Germany has an established hospital sterilization infrastructure deploying Getinge, STERIS, and Belimed sterilization equipment with strong domestic manufacturer presence.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, South Korea, India, and Australia represent the five largest national low temperature sterilization markets. Japan's Ministry of Health, Labour and Welfare enforces stringent reprocessing standards with Japanese hospital CSSD departments adopting hydrogen peroxide gas plasma for heat-sensitive instruments at academic medical centres. China's expanding surgical infrastructure including robotic surgery programme development at tier-1 and tier-2 hospitals expands the heat-sensitive instrument pool requiring low temperature sterilization, driving ASP, STERIS, and Getinge equipment procurement.

The markets in Latin America and Middle East and Africa are expected to register moderate revenue growth rates over the forecast period. Brazil, Mexico, Colombia, Argentina, and Chile represent the primary LatAm markets. Brazil's ANVISA Resolution RDC 15 establishes the regulatory framework for sterile processing in Brazilian hospitals. Saudi Arabia's Vision 2030 hospital expansion programme is commissioning central sterile supply departments equipped with STERRAD hydrogen peroxide gas plasma and STERIS VHP systems at new tertiary hospitals.